Pathogenic Cav3.2 channel mutation in a child with primary generalized epilepsy

Ivana A Souza1, Maria A Gandini1, Fang-Xiong Zhang1

  • 1Department of Physiology and Pharmacology, Alberta Children's Hospital Research Institute, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, 3330 Hospital Dr. NW, Calgary, AB, T2N 4N1, Canada.

Molecular Brain
|October 26, 2019
PubMed

Insights

Two CACNA1H gene variants were studied in a child with generalized epilepsy. One variant showed a gain-of-function effect, suggesting a role in epilepsy pathogenesis.

Area of Science:

  • Neurogenetics
  • Ion channel research
  • Epilepsy genetics

Background:

  • Generalized epilepsy is a neurological disorder with diverse genetic underpinnings.
  • The CACNA1H gene encodes a T-type calcium channel subunit (Cav3.2), implicated in neuronal excitability.
  • Understanding the genetic variants associated with epilepsy is crucial for diagnosis and treatment.

Observation:

  • A 6-year-old child presented with febrile and unprovoked seizures.
  • Two paternally inherited missense variants in the CACNA1H gene were identified in the patient.
  • These variants were expressed in vitro using human recombinant Cav3.2 channels.

Findings:

  • Electrophysiological recordings revealed that the c.3844C>T (p.R1282W) variant resulted in a significant increase in current density.
  • This gain-of-function phenotype suggests pathogenicity.
  • The co-inherited c.5294C>T (p.A1765V) variant exhibited a benign functional profile.

Implications:

  • The p.R1282W variant in CACNA1H may contribute to generalized epilepsy through a gain-of-function mechanism.
  • This finding highlights the importance of Cav3.2 channels in epilepsy pathogenesis.
  • Further research into CACNA1H variants could lead to novel therapeutic strategies for epilepsy.

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
579
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
772
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.1K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.5K